This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McPake, C. R. Articles by Harris, L. C. Search for Related Content PubMed PubMed Citation Articles by McPake, C. R. Articles by Harris, L. C.

Wild-Type p53 Induction Mediated by Replication-deficient Adenoviral Vectors¹

Departments of Molecular Pharmacology [C. R. M., S. S., L. C. H.] and Cell and Gene Therapy [G. R. K.], St. Jude Children’s Research Hospital, Memphis, Tennessee 38105

Replication-deficient E1-/E3-deleted adenoviral vectors are commonly used to introduce transgenes into cells in vitro and have been used for certain kinds of gene therapy protocols in vivo. We have demonstrated that transduction of cells using these vectors can induce p53 expression in cells containing a wild-type p53 gene. This response is different from p53 induction observed after DNA damage because the time course of induction is slower and because it occurs in cells with an attenuated DNA damage response. However, this vector-induced p53 is transcriptionally active and, therefore, p53 function is not inactivated by viral proteins. The mechanism of induction appears to be an increased rate of protein translation because immunoprecipitation analyses demonstrated increased levels of ³⁵S-labeled p53 protein, even after a short 15-min labeling time. Induction of p53 by adenoviral vectors may have various effects on transduced cells, including apoptosis and altered chemotherapy chemosensitivity. Therefore, the influence of the vector might confound the impact of any particular gene used in a gene therapy application.

This article has been cited by other articles:

				F. F. Lang, J. M. Bruner, G. N. Fuller, K. Aldape, M. D. Prados, S. Chang, M. S. Berger, M. W. McDermott, S. M. Kunwar, L. R. Junck, et al. Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results J. Clin. Oncol., July 1, 2003; 21(13): 2508 - 2518. [Abstract] [Full Text] [PDF]

				P. P. McKenzie, M. K. Danks, R. W. Kriwacki, and L. C. Harris p21Waf1/Cip1 Dysfunction in Neuroblastoma: A Novel Mechanism of Attenuating G0-G1 Cell Cycle Arrest Cancer Res., July 1, 2003; 63(13): 3840 - 3844. [Abstract] [Full Text] [PDF]

				M. Wierdl, C. L. Morton, L. C. Harris, M. K. Danks, J. D. Schuetz, and P. M. Potter p53-Mediated Regulation of Expression of a Rabbit Liver Carboxylesterase Confers Sensitivity to 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 699 - 705. [Abstract] [Full Text] [PDF]

				K. N. Fish, S. L. Schmid, and H. Damke Evidence That Dynamin-2 Functions as a Signal-Transducing Gtpase J. Cell Biol., July 10, 2000; 150(1): 145 - 154. [Abstract] [Full Text] [PDF]